Literature DB >> 8674055

Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma.

K Suzuki1, N Hayashi, Y Miyamoto, M Yamamoto, K Ohkawa, Y Ito, Y Sasaki, Y Yamaguchi, H Nakase, K Noda, N Enomoto, K Arai, Y Yamada, H Yoshihara, T Tujimura, K Kawano, K Yoshikawa, T Kamada.   

Abstract

Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) is unique in its ability to promote vascular permeability and endothelial cell growth, and its role in tumor development has received considerable attention. In this report, we describe the elevation of VPF/VEGF transcript expression in human hepatocellular carcinoma. Surgical samples of 23 patients with hepatocellular carcinoma were studied using reverse transcription-PCR analysis. The oligonucleotide primers were designed to amplify all four known splicing variants that could be expressed in the samples studied. Sixteen cases showed VPF/VEGF transcript expression in the tumor (16/23, 69.6%), whereas only 9 of the 23 patients showed it in the corresponding nontumoral part. There was no difference between the pattern of expression of VPF/VEGF isoforms in tumoral and nontumoral tissues. VPF/VEGF mRNA expression in the liver tumors was associated with fibrous capsule formation and septal formation (P < 0.05 respectively, Fisher's exact P test). In situ hybridization confirmed the presence of VPF/VEGF mRNA expression in tumor cells and less intensely in hepatocytes of nontumoral liver. We also found that VPF/VEGF expression in the tumor cell was increased in the area adjacent to necrotic regions (presumably hypoxic regions). As a regulator of vascular permeability and endothelial cell growth factor, VPF/VEGF may play an important role in the development of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674055

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

2.  Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients.

Authors:  Hatem A El-mezayen; Hossam Darwish
Journal:  Tumour Biol       Date:  2014-04-01

3.  Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.

Authors:  Gang Han; Yan Wang; Wenzhi Bi; Jinpeng Jia; Wei Wang; Meng Xu
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

4.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

Review 5.  Hepatic stellate cells in liver development, regeneration, and cancer.

Authors:  Chunyue Yin; Kimberley J Evason; Kinji Asahina; Didier Y R Stainier
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

6.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

7.  High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma.

Authors:  Yang Lv; Wei Wang; Wei-Dong Jia; Qi-Kai Sun; Jian-Sheng Li; Jin-Liang Ma; Wen-Bin Liu; Hang-Cheng Zhou; Yong-Sheng Ge; Ji-Hai Yu; Hong-Hai Xia; Ge-Liang Xu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

8.  Expression of TNF-alpha and VEGF in the esophagus of portal hypertensive rats.

Authors:  Zhao-Hui Yin; Xun-Yang Liu; Rang-Lang Huang; Shu-Ping Ren
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

9.  New pharmacological developments in the treatment of hepatocellular cancer.

Authors:  Niraj J Gusani; Yixing Jiang; Eric T Kimchi; Kevin F Staveley-O'Carroll; Hua Cheng; Jaffer A Ajani
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.

Authors:  Kai Wu; Liucheng Yang; Zonghai Huang; Haijun Zhao; Jianjun Wang; Shuai Xu
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.